5.86
+0.03(+0.51%)
Currency In USD
| Previous Close | 5.83 |
| Open | 5.83 |
| Day High | 5.95 |
| Day Low | 5.81 |
| 52-Week High | 12.83 |
| 52-Week Low | 4.39 |
| Volume | 94,054 |
| Average Volume | 474,306 |
| Market Cap | 418.43M |
| PE | 4.84 |
| EPS | 1.21 |
| Moving Average 50 Days | 6.35 |
| Moving Average 200 Days | 7.61 |
| Change | 0.03 |
If you invested $1000 in SIGA Technologies, Inc. (SIGA) 10 years ago, it would be worth $4,687.6 as of February 05, 2025 at a share price of $5.86. Whereas If you bought $1000 worth of SIGA Technologies, Inc. (SIGA) shares 5 years ago, it would be worth $1,323.56 as of February 05, 2025 at a share price of $5.86.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses
GlobeNewswire Inc.
Jan 02, 2025 12:30 PM GMT
Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan Biotechno Pharma Co., Ltd. engaged as exclusive distributor to supply TEPOXX to Japan’s national stockpile
Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced
GlobeNewswire Inc.
Dec 10, 2024 9:00 PM GMT
Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults affirm tecovirimat’s strong safety profileEff
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2024
GlobeNewswire Inc.
Nov 07, 2024 9:05 PM GMT
Product Revenues for the Three and Nine months Ended September 30, 2024 were $9 million and $53 million, respectivelyReceived $122 Million of Procurement Orders from the U.S. Government in the Third QuarterCorporate Update Conference Call Today at 4: